News
AVEO
15.00
0.00%
0.00
AVEO Completes Acquisition by LG Chem
AVEO Completes Acquisition by LG Chem
MT Newswires · 01/20 04:19
AVEO Pharmaceuticals Receives CFIUS Clearance for LG Chem Merger
AVEO Pharmaceuticals Receives CFIUS Clearance for LG Chem Merger
MT Newswires · 01/18 14:44
Aveo Oncology Form 8 Filing, Closing Of The Merger Is Expected To Occur On January 19, 2023
Benzinga · 01/18 13:54
On Jan 17, Aveo Oncology's Lg Chem Received Written Notice From CFIUS That There Were No Unresolved National Security Concerns Regarding Transaction; All Required Regulatory Approvals To Complete Merger Have Now Been Received
Benzinga · 01/18 13:53
Aveo Oncology shareholders approve acquisition by LG Chem
Seeking Alpha · 01/06 11:22
Reported Late Thursday, AVEO Oncology Stockholders Approve Acquisition By LG Chem; AVEO Stockholders Will Receive $15.00 Per Share In Cash Upon The Closing Of The Transaction
Benzinga · 01/06 05:40
AVEO Pharmaceuticals Stockholders Approve LG Chem Merger
AVEO Pharmaceuticals Stockholders Approve LG Chem Merger
MT Newswires · 01/06 03:28
BRIEF-Aveo Oncology - Effective As Of 1159 P.M. Eastern Time On December 1, 2022, Waiting Period Under Hart-Scott-Rodino Act Expired With Respect To Lg Chem Merger
Reuters · 12/02/2022 14:13
Aveo Oncology Says Effective As Of 11:59 p.m. Eastern Time On December 1, 2022, Waiting Period Under HSR Act Expired With Respect To LG Chem Merger
Benzinga · 12/02/2022 14:10
AVEO Pharmaceuticals Granted U.S. Patent #11504365: Use of tivozanib to treat subjects with refractory cancer
Benzinga · 11/22/2022 12:57
Mirati's (MRTX) Stock Rises on Q3 Earnings and Sales Beat
Mirati Therapeutics (MRTX) reports narrower-than-expected Q3 loss. Revenues also beat the mark. Stock rises in after-hours trading.
Zacks · 11/09/2022 14:47
What 4 Analyst Ratings Have To Say About AVEO Pharmaceuticals
Benzinga · 11/08/2022 13:59
Stifel Downgrades AVEO Pharmaceuticals to Hold, Announces $15 Price Target
Benzinga · 11/08/2022 11:13
--Stifel Downgrades AVEO Pharmaceuticals to Hold From Buy, Price Target is $15
--Stifel Downgrades AVEO Pharmaceuticals to Hold From Buy, Price Target is $15
MT Newswires · 11/08/2022 08:23
BRIEF-Aveo Oncology Reports Third Quarter 2022 Financial Results
Reuters · 11/07/2022 22:35
AVEO Pharmaceuticals GAAP EPS of -$0.09 beats by $0.08, revenue of $30.4M beats by $0.54M
Seekingalpha · 11/07/2022 21:52
AVEO Pharmaceuticals Q3 EPS $(0.09) Beats $(0.18) Estimate, Sales $30.45M Beat $29.55M Estimate
Benzinga · 11/07/2022 21:46
-- Earnings Flash (AVEO) AVEO PHARMACEUTICALS Reports Q3 Revenue $30.4M, vs. Street Est of $29.9M
-- Earnings Flash (AVEO) AVEO PHARMACEUTICALS Reports Q3 Revenue $30.4M, vs. Street Est of $29.9M
MT Newswires · 11/07/2022 16:24
Cancer drugs launch prices soaring, straining Medicare, report finds
Seekingalpha · 11/03/2022 16:30
More
Webull provides a variety of real-time AVEO stock news. You can receive the latest news about Aveo Pharma through multiple platforms. This information may help you make smarter investment decisions.
About AVEO
AVEO Pharmaceuticals, Inc. is an oncology-focused biopharmaceutical company. The Company is focused on delivering medicines for patients with cancer. The Company’s commercial product include FOTIVDA (tivozanib), which is an oral, vascular endothelial growth factor receptor (VEGFR) and tyrosine kinase inhibitor (TKI). The Company markets FOTIVDA (tivozanib) in the United States for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. It also develops FOTIVDA in immuno-oncology combinations in refractory RCC and other indications and has several other investigational programs in clinical development. The Company’s pipeline of product candidates includes ficlatuzumab, AV-380, AV-203 and AV-353. Its ficlatuzumab is a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor (HGF).